12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)

Ejemplares similares

• Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
  por: Kuemmerle-Deschner, Jasmin B, et al.
  Publicado: (2011)
• The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
  por: Wittkowski, H, et al.
  Publicado: (2008)
• 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
  por: Ruperto, N, et al.
  Publicado: (2008)
• Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
  por: Toker, Ori, et al.
  Publicado: (2010)
• Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
  por: Kuemmerle-Deschner, J, et al.
  Publicado: (2015)